Sarepta Therapeutics Inc (SRPT) 16.12 $SRPT
Why Sarepta Therapeutics Inc. Stock Imploded in October
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 7:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage developer of RNA-based therapeutics that's primarily focused on creating drugs designed to treat Duchenne muscular dystrophy (DMD), imploded in October and sank by...
RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), GSK: 44.91 (+0.16)
Sarepta Therapeutics tops 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:51AM CST
CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a third-quarter loss of $29.2 million.
SRPT: 16.12 (-0.14)
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments
Business Wire - Thu Nov 06, 6:01AM CST
--- New Drug Application submission for eteplirsen planned for mid-year 2015 based on recent FDA guidance -
SRPT: 16.12 (-0.14)
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:48AM CST
Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics may be one such company.
SRPT: 16.12 (-0.14)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 95.84 (+2.93), CYTX: 0.43 (-0.07), ACHN: 10.11 (-0.15), INCY: 69.32 (+0.92), SRPT: 16.12 (-0.14)
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Tue Nov 04, 6:01AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
SRPT: 16.12 (-0.14)
Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014
Business Wire - Fri Oct 31, 2:30PM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014. Subsequently, at 8:00 a.m. Eastern Time, Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.
SRPT: 16.12 (-0.14)
Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
at The Street - Fri Oct 31, 5:40AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RNA: 12.14 (+0.08), HEB: 0.29 (-0.01), SRPT: 16.12 (-0.14), ARNA: 4.26 (+0.01)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 320.75 (-2.72), CBST: 70.38 (-0.53), MDCO: 24.59 (+0.32), SRPT: 16.12 (-0.14), ALXN: 193.81 (+0.67), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
AMKR: 6.39 (-0.14), MXWL: 11.15 (-0.09), PCMI: 7.45 (-3.15), SRPT: 16.12 (-0.14), REXX: 8.00 (+0.50), WIRE: 40.39 (-0.16), LMNX: 18.04 (-0.75), PDCE: 42.77 (+2.58)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.39 (-0.14), KSS: 57.22 (+0.41), MU: 33.01 (-0.34), PFE: 29.92 (-0.12), HAL: 53.86 (+0.69), AMGN: 160.25 (-0.10), NQ: 7.18 (+0.20), RGC: 22.15 (-0.07), MS: 35.66 (+0.35), MSG: 75.15 (+0.27), NVAX: 4.95 (-0.20), CQB: 14.43 (+0.01), SRPT: 16.12 (-0.14), RCPT: 109.24 (-1.28), TWTR: 40.31 (-0.53), PTIE: 1.71 (-0.11)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 320.75 (-2.72), RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), AMAG: 34.95 (+0.83)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.23 (+0.16), MRK: 59.34 (+0.08), PFE: 29.92 (-0.12), SRPT: 16.12 (-0.14), NLNK: 32.15 (-2.54), TKMR: 16.75 (+0.99), GSK: 44.91 (+0.16), NVS: 91.76 (-0.27)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 320.75 (-2.72), SRPT: 16.12 (-0.14), AMAG: 34.95 (+0.83), ARRY: 3.88 (+0.02)
Sarepta tumbles on drug delay
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The Cambridge, Mass.-based biotech's shares plummeted 32.5% to 15.91 after it said that the FDA is requiring more extensive information about its muscular dystrophy treatment, eteplirsen, before it will approve the drug. The announcement comes after...
SRPT: 16.12 (-0.14)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 171.22 (-0.48), BX: 31.14 (+0.84), NKE: 93.78 (-0.82), XBI: 167.72 (-1.28), GRMN: 54.70 (-0.24), PCL: 41.38 (+0.20), UPS: 108.33 (+0.04), TCBI: 61.57 (+0.22), UA: 66.98 (+0.70), SPY: 203.34 (+0.19), QQQ: 101.60 (-0.09), MPC: 94.08 (+0.95), SRPT: 16.12 (-0.14), MRK: 59.34 (+0.08), DIA: 175.58 (+0.29), STI: 39.66 (-0.16), CFG: 23.97 (-0.33), TEVA: 57.70 (-1.02), FL: 54.50 (+0.03), AAPL: 109.01 (+0.31), XLE: 87.79 (+0.96)
Petrobras Plunges In The Wake Of Brazilian Election Results
at The Street - Mon Oct 27, 12:15PM CDT
Odyssey Marine Exploration Inc (NASDAQ:OMEX), Tasman Metals Ltd (NYSEMKT:TAS) and ANADIGICS, Inc. (NASDAQ:ANAD) got a strong start to the day, making notable gains early this Monday. In the red are¿...
PBR: 10.90 (+0.17), CJES: 19.14 (+1.13), OMEX: 1.18 (+0.02), ANAD: 0.77 (-0.01), SRPT: 16.12 (-0.14)
Why Sarepta Therapeutics Inc Stock Is Crashing Today
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of clinical-stage biotech Sarepta...
SRPT: 16.12 (-0.14)
Sarepta Shares Falls on Duchenne Drug Approval Filing Delay
at The Street - Mon Oct 27, 10:02AM CDT
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14)
Why Sarepta Therapeutics Inc. Stock Imploded in October
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 7:04AM CST
SRPT data by YCharts What: Shares of Sarepta Therapeutics , a clinical-stage developer of RNA-based therapeutics that's primarily focused on creating drugs designed to treat Duchenne muscular dystrophy (DMD), imploded in October and sank by...
RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), GSK: 44.91 (+0.16)
Sarepta Therapeutics tops 3Q profit forecasts
Automated Insights - Thu Nov 06, 6:51AM CST
CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a third-quarter loss of $29.2 million.
SRPT: 16.12 (-0.14)
Sarepta Therapeutics Announces Third Quarter 2014 Financial Results and Recent Corporate Developments
Business Wire - Thu Nov 06, 6:01AM CST
--- New Drug Application submission for eteplirsen planned for mid-year 2015 based on recent FDA guidance -
SRPT: 16.12 (-0.14)
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:48AM CST
Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics may be one such company.
SRPT: 16.12 (-0.14)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 95.84 (+2.93), CYTX: 0.43 (-0.07), ACHN: 10.11 (-0.15), INCY: 69.32 (+0.92), SRPT: 16.12 (-0.14)
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Business Wire - Tue Nov 04, 6:01AM CST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
SRPT: 16.12 (-0.14)
Sarepta Therapeutics to Announce Third Quarter 2014 Financial Results and Corporate Update on November 6, 2014
Business Wire - Fri Oct 31, 2:30PM CDT
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014. Subsequently, at 8:00 a.m. Eastern Time, Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.
SRPT: 16.12 (-0.14)
Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx
at The Street - Fri Oct 31, 5:40AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
RNA: 12.14 (+0.08), HEB: 0.29 (-0.01), SRPT: 16.12 (-0.14), ARNA: 4.26 (+0.01)
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Oct 29, 11:28AM CDT
Quite a few biotech companies fared well i the third quarter with earnings surpassing expectations and guidance being raised.
BIIB: 320.75 (-2.72), CBST: 70.38 (-0.53), MDCO: 24.59 (+0.32), SRPT: 16.12 (-0.14), ALXN: 193.81 (+0.67), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
AMKR: 6.39 (-0.14), MXWL: 11.15 (-0.09), PCMI: 7.45 (-3.15), SRPT: 16.12 (-0.14), REXX: 8.00 (+0.50), WIRE: 40.39 (-0.16), LMNX: 18.04 (-0.75), PDCE: 42.77 (+2.58)
Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.39 (-0.14), KSS: 57.22 (+0.41), MU: 33.01 (-0.34), PFE: 29.92 (-0.12), HAL: 53.86 (+0.69), AMGN: 160.25 (-0.10), NQ: 7.18 (+0.20), RGC: 22.15 (-0.07), MS: 35.66 (+0.35), MSG: 75.15 (+0.27), NVAX: 4.95 (-0.20), CQB: 14.43 (+0.01), SRPT: 16.12 (-0.14), RCPT: 109.24 (-1.28), TWTR: 40.31 (-0.53), PTIE: 1.71 (-0.11)
Sarepta Slumps as Eteplirsen NDA Submission Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 1:22PM CDT
Sarepta Therapeutics (SRPT) shares plunged 32.5% on news that the company will not be submitting its NDA for eteplirsen.
BIIB: 320.75 (-2.72), RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), AMAG: 34.95 (+0.83)
Time Magazine Warns Against Investing In Certain "Ebola Stocks"
ACCESSWIRE - Tue Oct 28, 8:22AM CDT
LOS ANGELES, CA / ACCESSWIRE / October 28, 2014 / Time Magazine is today warning investors that while developmental stage pharmas like Inovio Pharmaceuticals (NASDAQ:INO , NewLink Genetics Corp. (NASDAQ:NLNK), Tekmira Pharmaceuticals (NASDAQ:TKMR) and Sarepta Therapeutics (NASDAQ:SRPT) have all generated significant interest among stock market investors lately, there are good reasons to shy away from buying into experimental Ebola treatment therapies. But how can this be?
INO: 11.23 (+0.16), MRK: 59.34 (+0.08), PFE: 29.92 (-0.12), SRPT: 16.12 (-0.14), NLNK: 32.15 (-2.54), TKMR: 16.75 (+0.99), GSK: 44.91 (+0.16), NVS: 91.76 (-0.27)
Sarepta Slumps: SRPT Plunges 32.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:49AM CDT
Sarepta has been witnessing a flat trend in its current earnings estimate and it share price has been falling for past few days
BIIB: 320.75 (-2.72), SRPT: 16.12 (-0.14), AMAG: 34.95 (+0.83), ARRY: 3.88 (+0.02)
Sarepta tumbles on drug delay
at Investor's Business Daily - Mon Oct 27, 5:55PM CDT
The Cambridge, Mass.-based biotech's shares plummeted 32.5% to 15.91 after it said that the FDA is requiring more extensive information about its muscular dystrophy treatment, eteplirsen, before it will approve the drug. The announcement comes after...
SRPT: 16.12 (-0.14)
Can U.S. Stocks Go Higher if Oil Prices Keep Going Lower?
at The Street - Mon Oct 27, 1:56PM CDT
The "Fast Money" trading panel discussed the impact of falling oil prices on the stock market.
FDX: 171.22 (-0.48), BX: 31.14 (+0.84), NKE: 93.78 (-0.82), XBI: 167.72 (-1.28), GRMN: 54.70 (-0.24), PCL: 41.38 (+0.20), UPS: 108.33 (+0.04), TCBI: 61.57 (+0.22), UA: 66.98 (+0.70), SPY: 203.34 (+0.19), QQQ: 101.60 (-0.09), MPC: 94.08 (+0.95), SRPT: 16.12 (-0.14), MRK: 59.34 (+0.08), DIA: 175.58 (+0.29), STI: 39.66 (-0.16), CFG: 23.97 (-0.33), TEVA: 57.70 (-1.02), FL: 54.50 (+0.03), AAPL: 109.01 (+0.31), XLE: 87.79 (+0.96)
Petrobras Plunges In The Wake Of Brazilian Election Results
at The Street - Mon Oct 27, 12:15PM CDT
Odyssey Marine Exploration Inc (NASDAQ:OMEX), Tasman Metals Ltd (NYSEMKT:TAS) and ANADIGICS, Inc. (NASDAQ:ANAD) got a strong start to the day, making notable gains early this Monday. In the red are¿...
PBR: 10.90 (+0.17), CJES: 19.14 (+1.13), OMEX: 1.18 (+0.02), ANAD: 0.77 (-0.01), SRPT: 16.12 (-0.14)
Why Sarepta Therapeutics Inc Stock Is Crashing Today
George Budwell, The Motley Fool - Motley Fool - Mon Oct 27, 12:05PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of clinical-stage biotech Sarepta...
SRPT: 16.12 (-0.14)
Sarepta Shares Falls on Duchenne Drug Approval Filing Delay
at The Street - Mon Oct 27, 10:02AM CDT
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14)
